{"id":1662,"date":"2022-11-03T20:05:36","date_gmt":"2022-11-03T17:05:36","guid":{"rendered":"https:\/\/www.sightsciences.com\/us\/?p=1662"},"modified":"2024-05-28T12:45:44","modified_gmt":"2024-05-28T09:45:44","slug":"publication-of-omni-standalone-effectiveness","status":"publish","type":"post","link":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/","title":{"rendered":"Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI\u00ae Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure"},"content":{"rendered":"<div class=\"ndq-section\">\n<div id=\"ndq-content\" class=\"row ndq-7591\">\n<div class=\"column large-12\">\n<div class=\"region region-content\">\n<div class=\"hidden\" data-drupal-messages-fallback=\"\"><\/div>\n<div id=\"block-nir-pid4158-content\" class=\"block--system-main-block block--system-main-block--7591 block--content--system-main-block block--content--system-main-block--7591 block--d3e5cab3-701e-469f-8150-a0c2ef34d4c7 block--d3e5cab3-701e-469f-8150-a0c2ef34d4c7--7591 block block-system block-system-main-block\">\n<article class=\"node node--nir-news--full node--type-nir-news node--view-mode-full node--promoted\">\n<div class=\"file-link pdf-file-link\"><span class=\"file file--mime-application-pdf file--application-pdf\"><a href=\"\/us\/wp-content\/uploads\/sites\/4\/2023\/09\/OMNI-Publication-Clinical-Data.pdf\" target=\"_blank\" rel=\"noopener\">PDF Version<\/a><\/span><\/div>\n<p>&nbsp;<\/p>\n<div class=\"node__content\">\n<div class=\"box__wrap\"><\/div>\n<h3 class=\"subhead-gnw\">Multicenter Clinical Data from Five US sites Published in International Ophthalmology<\/h3>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"margin-bottom: 8pt;\"><em>Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery.<\/em><\/li>\n<li style=\"margin-bottom: 8pt;\"><em>Despite glaucoma medications and prior microbypass stenting, target IOP may no longer be achieved over time.<\/em><\/li>\n<li style=\"margin-bottom: 8pt;\"><em>During 3 to 42 months follow-up, the majority of these standalone study patients treated with OMNI regained IOP control and avoided traditional surgery.<\/em><\/li>\n<\/ul>\n<p>MENLO PARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) &#8212; Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients\u2019 lives, today announced International Ophthalmology has published clinical data\u00a0demonstrating the safety and effectiveness of the OMNI Surgical System as a minimally invasive, implant-free standalone (not in combination with cataract surgery) glaucoma procedure for pseudophakic glaucoma patients with a history of trabecular microbypass stent implantation (iStent<sup>\u00ae<\/sup> or iStent Inject<sup>\u00ae<\/sup>) whose pressure is no longer controlled by the bypass stent and IOP-lowering medications.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p>\u201cGlaucoma is a chronic disease, and most patients will need a variety of treatments over the course of their lives. Compliance with daily glaucoma medications can be low, and depending on the patient and stage of disease progression, some interventions such as bypass stents and\/or IOP-lowering medications may run their natural course and no longer control the disease,\u201d said Deepan Selvadurai, MD, a glaucoma specialist and cataract surgeon at Buffalo Ophthalmology in Buffalo, New York, and a clinical investigator and co-author of the study. \u201cThe OMNI Surgical System offers a potent implant-free procedure that I have found to be effective and durable in my pseudophakic patients where I had previously implanted trabecular bypass stents at the time of cataract surgery. This study showed that canaloplasty followed by trabeculotomy with OMNI as a standalone procedure in pseudophakic eyes with stents was highly effective in reducing IOP.\u201d<br class=\"\" \/><br class=\"\" \/><\/p>\n<p>The OMNI Surgical System is an implant-free procedure that uniquely addresses all three known points of resistance in the aqueous outflow system: the trabecular meshwork, Schlemm\u2019s canal, and the collector channels. Because it offers a comprehensive mechanism of action through sequential canaloplasty and trabeculotomy, OMNI surgeons can successfully intervene in the same conventional outflow pathway anatomy when trabecular bypass implants and medications are no longer able to control IOP.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p>\u201cMore than one million eyes have received trabecular microbypass stent implants. Over time, these patients may progress to the point where their IOP is no longer adequately controlled by the implant and\/or IOP-lowering medications,\u201d said Paul Badawi, CEO and co-founder of Sight Sciences. \u201cSubstantial data supports OMNI\u2019s effectiveness in combination with cataract surgery as well as its standalone use. This important multi-center data shows that OMNI can also help our customers address this large, existing, and growing subset of pseudophakic stented glaucoma patients. We view this as additional validation that OMNI has the unique potential to provide benefit throughout the entire life cycle of glaucoma disease \u2013 performed before, during, and after cataract surgery.\u201d<br class=\"\" \/><br class=\"\" \/><\/p>\n<p>Authors and affiliations: Daniel C. Terveen MD, Adam R. Bleeker MD of Vance Thompson Vision, Steven R. Sarkisian Jr., MD of Oklahoma Eye Surgeons, Steven D. Vold MD of Vold Vision, Deepan Selvadurai MD of Buffalo Ophthalmology, Blake K. Williamson MD, The Williamson Eye Center, Deborah G. Ristvedt MD of Vance Thompson Vision, Kavita Dhamdhere Phd of Sight Sciences and Mahatma Gandhi Medical College, Jaime E. Dickerson Jr., PhD, of Sight Sciences and North Texas Eye Research Institute.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p>Paper Reference: Terveen, D.C., Sarkisian, S.R., Vold, S.D.\u00a0<em>et al.<\/em>\u00a0Canaloplasty and trabeculotomy with the OMNI<sup>\u00ae<\/sup>\u00a0surgical system in OAG with prior trabecular microbypass stenting.\u00a0<em>Int Ophthalmol<\/em>\u00a0(2022). <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eCVYg-bhMMBMEZTT8DPzWxt_BKfIF4UN3mC7owgsQZcaYBEQWsJLYnFC-roGJGKu6O9Tke-TLP2-ihKmQURb3zW0xjS2zt4-YmgF06MrE3gMQbkZEaGKg_TVvcLQuH4Amq7BvnEagTkm1Br2d2BMUg==\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/doi.org\/10.1007\/s10792-022-02553-6<\/a><br class=\"\" \/><br class=\"\" \/><\/p>\n<p>iStent and iStent Inject are registered trademarks of Glaukos Corporation.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p><strong>About the OMNI<\/strong><sup><strong>\u00ae<\/strong><\/sup><strong> Surgical System<\/strong><br class=\"\" \/><br class=\"\" \/><\/p>\n<p>The OMNI<sup>\u00ae<\/sup> Surgical System is a handheld, single-use therapeutic device for minimally invasive glaucoma surgery (MIGS). It is indicated for canaloplasty (the microcatheterization and viscodilation of Schlemm\u2019s canal) followed by trabeculotomy (the cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p>Through a single clear corneal microincision, OMNI allows surgeons to access all 360 degrees of Schlemm\u2019s canal and treat all three sources of outflow resistance within the eye\u2019s diseased conventional outflow pathway (trabecular meshwork, Schlemm\u2019s canal, and collector channels).<br class=\"\" \/><br class=\"\" \/><\/p>\n<p>OMNI is indicated by the FDA for canaloplasty (the microcatheterization and viscodilation of Schlemm\u2019s canal) followed by trabeculotomy (the cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma. OMNI has a CE Mark for the catheterization and transluminal viscodilation of Schlemm\u2019s canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p>OMNI should not be used in any situations where the iridocorneal angle is compromised or has been damaged since it may not be possible to visualize the angle or to properly pass the microcatheter. Do not use the OMNI in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris or in quadrants with previous MIGS implants.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p>OMNI received its first FDA clearance in 2017 and is protected by a global patent portfolio including 32 issued patents worldwide.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p>OMNI is a registered trademark of Sight Sciences.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pGtH30QpGkwXRUkq8SkuhvlU_Xh9GHVxs_H_FxrU8nf2MFatLZ-sy-T45yVET86t2hiEsHdNu4TEVYGJoXRs__rggDDwaS0MXEJ-ghMFOjA=\" target=\"_blank\" rel=\"nofollow noopener\">www.OMNIsurgical.com<\/a>.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p><strong>About Sight Sciences<\/strong><br class=\"\" \/><br class=\"\" \/><\/p>\n<p>Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients\u2019 lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world\u2019s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0zXTf_EovfwlpKfMz2rl5_b-tS7fVEQA8dEtwRHdMONmRLBSFWSLivejLXvKy_vX-7rqDB4xlmpn2TZ2Fyktqg==\" target=\"_blank\" rel=\"nofollow noopener\">OMNI<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1X68zc-15EB4stAs6NoSM2vbfYIWkrnFPnM_YEob-LJnxzVgn0XOAvL2zVDwdJAcVLTqu4PFhVbe31i7Yzlqgw==\" target=\"_blank\" rel=\"nofollow noopener\"><sup>\u00ae<\/sup><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gp1M4w14zYDkqQ0PvM46Z9IX74iivAxLQ-8rbDLzsGBJN9WS9hwhVdPdZY3wLDB83-cFEp-aynffUa690Ia-kS85kSFgqJ3_L-MhGMnShBY=\" target=\"_blank\" rel=\"nofollow noopener\"> Surgical System<\/a> is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world\u2019s leading cause of irreversible blindness. The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y4E8Rexx4cAqyrTB-UxygcJNVRPZKOVdcvNILvzeFmHfUTdMSoCfbU3r9eFjrhzvrzITPlEb3hHToUw7PWnkYzU5qgTJ6Os6GBULaTr9SE4=\" target=\"_blank\" rel=\"nofollow noopener\">SION\u2122 Surgical Instrument<\/a> is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GbjcOFsP9P84RCBo-cDDc_r2WYvSLoavy_cnmqzft1O0yEDaF4iAiNIQgpLKLALbUgYbSrRJ8XAyqI9hZSVaNQ==\" target=\"_blank\" rel=\"nofollow noopener\">TearCare<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JZCqtLOWhfqfkfCFxwgna97hIbGh1zOm21w-lRXup1FEu1c2lNLJYr1Sykt2IpCa\" target=\"_blank\" rel=\"nofollow noopener\"><sup>\u00ae<\/sup><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V-2UkvrOmdarf0cT6gJfv-xKdhdZGKbv8fovn2_XjpvpLiXmYMmBBd8Iff3IBLkydjCkuLXXr5mzpiqCVM80dQ==\" target=\"_blank\" rel=\"nofollow noopener\"> System<\/a> is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=19gIcgxL5qboLZyHQRTS5AiTSKJ56lipOm5eDwsItF8e1_Da2r4SNmks_fdaATq24seOSomUbKUcwul5sUtUUZ6LCPEVRDCWqru39qf6eCg=\" target=\"_blank\" rel=\"nofollow noopener\">www.SightSciences.com<\/a>.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p><strong>Forward-Looking Statements<\/strong><br class=\"\" \/><br class=\"\" \/><\/p>\n<p>This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201csuggests,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cestimates,\u201d \u201ctargets,\u201d \u201cprojects,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cforecast\u201d and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. The forward-looking statements are subject to and involve risks, uncertainties and assumptions, and you should not place undue reliance on these forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the following: estimates of our total addressable market, future revenue, expenses, capital requirements, and our needs for additional financing; our ability to enter into and compete in new markets; the impact of the COVID-19 pandemic on our business, our customers\u2019 and suppliers\u2019 businesses and the general economy; our ability to compete effectively with existing competitors and new market entrants; our ability to scale our infrastructure; our ability to manage and grow our business by expanding our sales to existing customers or introducing our products to new customers; our ability to establish and maintain intellectual property protection for our products or avoid claims of infringement; potential effects of extensive government regulation; our abilities to obtain and maintain regulatory approvals and clearances for our products that support our revenue projections, business strategies and growth; our ability to successfully execute our clinical trial roadmap; our ability to obtain and maintain sufficient reimbursement for our products; our abilities to protect and scale our intellectual property portfolio; our ability to hire and retain key personnel; our ability to obtain financing in future offerings; the volatility of the trading price of our common stock; our expectation regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act (the \u201cJOBS Act\u201d); our ability to maintain proper and effective internal controls; and the other important factors discussed under the caption \u201cRisk Factors\u201d in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.<br class=\"\" \/><br class=\"\" \/><\/p>\n<p><strong>Media contact &#8211; Glaucoma:<\/strong><br \/>\nCarmen Caricchio<br \/>\nC2M Group<br \/>\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7-j3QgsVM7KZVv1AB8fOaa57zbhyhQ9sULIwWSOkdo8cDA_-zD9LtNbH31y0eJEK260pxPaYdRUeLOIIQMIInhR2IwBZXQ8XYxu6tkvROAM=\" target=\"_blank\" rel=\"nofollow noopener\">pr@sightsciences.com<\/a><br class=\"\" \/><br class=\"\" \/><\/p>\n<p><strong>Investor contact<\/strong>:<br \/>\nPhilip Taylor<br \/>\nGilmartin Group<br \/>\n415.937.5406<br \/>\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Pl7Zp4ou5tVsIb9bRUTgtJjJ0Pyf4XyEpvyUKU9s5S8PotiFt6PTgsADS1Fyibc5CfqD-YPAmGRRYy_4cDLOWVnrcWvjiAAQZJwvtNQMjkWIjYAY4WHhDprXTenU-gnYHZ45GGeAmBhygIM00Cq-wg==\" target=\"_blank\" rel=\"nofollow noopener\">Investor.Relations@Sightsciences.com<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDZkNmQ3NTItY2FhMi00ODlhLTk0NGYtM2E0MDdmMjJiNmZmLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png\" alt=\"\" \/><\/p>\n<\/div>\n<\/article>\n<\/div>\n<div id=\"block-nir-pid4158-websitenoticeblock\" class=\"block--website-notice-block block--website-notice-block--7591 block--content--website-notice-block block--content--website-notice-block--7591 block--4d7a5f5e-26bd-48f8-9ae6-c5112267a7f5 block--4d7a5f5e-26bd-48f8-9ae6-c5112267a7f5--7591 block block-nir-website-notices block-website-notice-block\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Multicenter Clinical Data from Five US sites Published in International Ophthalmology<br \/>\nWorldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery.<br \/>\nDespite glaucoma medications and prior microbypass stenting, target IOP may no longer be achieved over time.<br \/>\nDuring 3 to 42 months follow-up, the majority of these standalone study patients treated with OMNI regained IOP control and avoided traditional surgery.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[6,5],"tags":[],"class_list":["post-1662","post","type-post","status-publish","format-standard","hentry","category-news","category-omni"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI\u00ae Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure - United States<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI\u00ae Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure\" \/>\n<meta property=\"og:description\" content=\"Multicenter Clinical Data from Five US sites Published in International Ophthalmology Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery. Despite glaucoma medications and prior microbypass stenting, target IOP may no longer be achieved over time. During 3 to 42 months follow-up, the majority of these standalone study patients treated with OMNI regained IOP control and avoided traditional surgery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-03T17:05:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-28T09:45:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml.globenewswire.com\/media\/NDZkNmQ3NTItY2FhMi00ODlhLTk0NGYtM2E0MDdmMjJiNmZmLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png\" \/>\n<meta name=\"author\" content=\"admin-dev\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin-dev\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/\"},\"author\":{\"name\":\"admin-dev\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#\\\/schema\\\/person\\\/88f84507b2364aa1168168756f61f091\"},\"headline\":\"Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI\u00ae Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure\",\"datePublished\":\"2022-11-03T17:05:36+00:00\",\"dateModified\":\"2024-05-28T09:45:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/\"},\"wordCount\":1710,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/NDZkNmQ3NTItY2FhMi00ODlhLTk0NGYtM2E0MDdmMjJiNmZmLTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\",\"articleSection\":[\"News\",\"OMNI\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/\",\"url\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/\",\"name\":\"Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI\u00ae Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure - United States\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/NDZkNmQ3NTItY2FhMi00ODlhLTk0NGYtM2E0MDdmMjJiNmZmLTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\",\"datePublished\":\"2022-11-03T17:05:36+00:00\",\"dateModified\":\"2024-05-28T09:45:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#\\\/schema\\\/person\\\/88f84507b2364aa1168168756f61f091\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/NDZkNmQ3NTItY2FhMi00ODlhLTk0NGYtM2E0MDdmMjJiNmZmLTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\",\"contentUrl\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/NDZkNmQ3NTItY2FhMi00ODlhLTk0NGYtM2E0MDdmMjJiNmZmLTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/publication-of-omni-standalone-effectiveness\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI\u00ae Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#\\\/schema\\\/person\\\/88f84507b2364aa1168168756f61f091\",\"name\":\"admin-dev\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g\",\"caption\":\"admin-dev\"},\"url\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/author\\\/admin-dev\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI\u00ae Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure - United States","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/","og_locale":"en_US","og_type":"article","og_title":"Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI\u00ae Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure","og_description":"Multicenter Clinical Data from Five US sites Published in International Ophthalmology Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery. Despite glaucoma medications and prior microbypass stenting, target IOP may no longer be achieved over time. During 3 to 42 months follow-up, the majority of these standalone study patients treated with OMNI regained IOP control and avoided traditional surgery.","og_url":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/","og_site_name":"United States","article_published_time":"2022-11-03T17:05:36+00:00","article_modified_time":"2024-05-28T09:45:44+00:00","og_image":[{"url":"https:\/\/ml.globenewswire.com\/media\/NDZkNmQ3NTItY2FhMi00ODlhLTk0NGYtM2E0MDdmMjJiNmZmLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","type":"","width":"","height":""}],"author":"admin-dev","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin-dev","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/#article","isPartOf":{"@id":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/"},"author":{"name":"admin-dev","@id":"https:\/\/www.sightsciences.com\/us\/#\/schema\/person\/88f84507b2364aa1168168756f61f091"},"headline":"Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI\u00ae Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure","datePublished":"2022-11-03T17:05:36+00:00","dateModified":"2024-05-28T09:45:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/"},"wordCount":1710,"commentCount":0,"image":{"@id":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/#primaryimage"},"thumbnailUrl":"https:\/\/ml.globenewswire.com\/media\/NDZkNmQ3NTItY2FhMi00ODlhLTk0NGYtM2E0MDdmMjJiNmZmLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","articleSection":["News","OMNI"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/","url":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/","name":"Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI\u00ae Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure - United States","isPartOf":{"@id":"https:\/\/www.sightsciences.com\/us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/#primaryimage"},"image":{"@id":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/#primaryimage"},"thumbnailUrl":"https:\/\/ml.globenewswire.com\/media\/NDZkNmQ3NTItY2FhMi00ODlhLTk0NGYtM2E0MDdmMjJiNmZmLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","datePublished":"2022-11-03T17:05:36+00:00","dateModified":"2024-05-28T09:45:44+00:00","author":{"@id":"https:\/\/www.sightsciences.com\/us\/#\/schema\/person\/88f84507b2364aa1168168756f61f091"},"breadcrumb":{"@id":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/#primaryimage","url":"https:\/\/ml.globenewswire.com\/media\/NDZkNmQ3NTItY2FhMi00ODlhLTk0NGYtM2E0MDdmMjJiNmZmLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","contentUrl":"https:\/\/ml.globenewswire.com\/media\/NDZkNmQ3NTItY2FhMi00ODlhLTk0NGYtM2E0MDdmMjJiNmZmLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.sightsciences.com\/us\/publication-of-omni-standalone-effectiveness\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sightsciences.com\/us\/"},{"@type":"ListItem","position":2,"name":"Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI\u00ae Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure"}]},{"@type":"WebSite","@id":"https:\/\/www.sightsciences.com\/us\/#website","url":"https:\/\/www.sightsciences.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sightsciences.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.sightsciences.com\/us\/#\/schema\/person\/88f84507b2364aa1168168756f61f091","name":"admin-dev","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g","caption":"admin-dev"},"url":"https:\/\/www.sightsciences.com\/us\/author\/admin-dev\/"}]}},"_links":{"self":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/posts\/1662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/comments?post=1662"}],"version-history":[{"count":0,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/posts\/1662\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/media?parent=1662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/categories?post=1662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/tags?post=1662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}